Increased protein glycation in cirrhosis and therapeutic strategies to prevent it

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 718-724

  Ahmed, Naila ^a   Lüthen, Reinhard ^b   Häussinger, Dieter ^b   Šebeková, Katarína ^c   Schinzel, Reinhard ^d   Voelker, Wolfram ^d   Heidland, August ^d   Thornalley, Paul J ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Advanced glycation end products (AGEs); Cirrhosis; Fructosyl lysine; Glyoxal; Methylglyoxal; Oxidative stress; Reactive nitrogen species

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALCOHOL; ALDEHYDE DERIVATIVE; CARBONYL DERIVATIVE; GLUTATHIONE; GLYOXAL; IMIDAZOLE DERIVATIVE; LIVER PROTEIN; PROTEASOME; SCAVENGER; THIAMINE;

ALCOHOL LIVER CIRRHOSIS; CONFERENCE PAPER; HUMAN; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER INJURY; MASS SPECTROMETRY; NITROSATION; OXIDATION; PORTAL VEIN BLOOD FLOW; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SCREENING; VENOUS BLOOD;

EID: 23744447235     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.083     Document Type: Conference Paper

References (43)

1. BURROUGHS, A. & D. MCNAMARA. 2003. Liver disease in Europe. Aliment. Pharmacol. Ther. 18: 54-59.
2. LAVANCHY, D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatitis 11: 97-107.
3. HUTIN, Y., M.E. KITLER, G.J. DORE, et al. 2004. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44: 20-29.
4. POULETTY, P. 2002. Drug addictions: towards socially accepted and medically treatable diseases. Nat. Rev. Drug Disc. 1: 731-736.
5. IREDALE, J.P. 2003. Science, medicine, and the future. Cirrhosis: new research provides a basis for rational and targeted treatments. Br. Med. J. 327: 143-147.
6. FRIEDMAN, S.L. 2003. Liver fibrosis: from bench to bedside. J. Hepatol. 38: S38-S53.
7. NELSON, D.R., Z.K. TU, C. SOLDEVILA-PICO, et al. 2003. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38: 859-868.
8. TILG, H., R. JALAN, A. KASER, et al. 2003. Antitumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 38: 419-425.
9. WILLIS, M.S., L.W. KLASSEN, D.J. TUMA & G.M. THIELE. 2002. Malondialdehyde-acetaldehyde-haptenated protein induces cell death by induction of necrosis and apoptosis in immune cells. Intl. Immunopharmacol. 2: 519-535.
10. KHARBANDA, K.K., S.L. TODERO, K.A. SHUBERT, et al. 2001. Malondialdehyde-acetaldehyde-protein adducts increase secretion of chemokines by rat hepatic stellate cells. Alcohol 25: 123-128.
11. SEBEKOVA, K., V. KUPCOVA, R. SCHINZEL & A. HEIDLAND. 2002. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation. J. Hepatol. 36: 66-71.
12. BIANCHI, G., G. MARCHESINI, A. FABBRI, et al. 1997. Lipoperoxide plasma levels in patients with liver cirrhosis. Hepato-Gastroenterology 44: 784-788.
13. PARADIS, V., M. KOLLINGER, M. FABRE, et al. 1997. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 26: 135-142.
14. FATACCIOLI, V., E. ANDRAUD, S.W. FRENCH & H. ROUACH. 1999. Effects of chronic ethanol administration on rat liver proteasome activities: relationship with oxidative stress. Hepatology 29: 14-20.
15. AHMED, N., P.J. THORNALLEY, R. LUTHEN, et al. 2004. Processing of protein glycation, oxidation, and nitrosation adducts in the liver and the effect of cirrhosis. J. Hepatol. 41: 913-919.
16. THORNALLEY, P.J., S. BATTAH, N. AHMED, et al. 2003. Quantitative screening of advanced glycation end products in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375: 581-592.
17. 131I-tagged albumin. J. Clin. Invest. 30: 1238-1246.
18. THORNALLEY, P.J. 2003. The enzymatic defence against glycation in health, disease, and therapeutics: a symposium to examine the concept. Biochem. Soc. Trans. 31: 1343-1348.
19. SMEDSROD, B., J. MELKKO, N. ARAKI, et al. 1997. Advanced glycation end products are eliminated by scavenger receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem. J. 322: 567-573.
20. THORNALLEY, P.J., M. ARGIROVA, N. AHMED, et al. 2000. Mass spectrometric monitoring of albumin in uraemia. Kidney Int. 58: 2228-2234.
21. JOHNSON, R.N., R.W. EASDALE, M. TATNELL & J.R. BAKER. 1991. Significance of variation in turnover of glycated albumin on indexes of diabetic control. Clin. Chim. Acta 198: 229-238.
22. YAMASAKI, Y., K. SUMIMOTO, M. NISHIKAWA, et al. 2002. Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors. J. Pharmacol. Exp. Ther. 301: 467-477.
23. SVISTOUNOV, D.N., T.J. BERG, P.A.G. MCCOURT, et al. 2003. Lack of recognition of N-epsilon-(carboxymethyl)lysine by the mouse liver reticulo-endothelial system: implications for pathophysiology. Biochem. Biophys. Res. Comm. 309: 786-791.
24. HOPPE, G., J. O'NEIL, L.M. SAYRE & H.F. HOFF. 1997. Nonconventional modification of low density lipoproteins: chemical models for macrophage recognition of oxidized LDL. Biochim. Biophys. Acta Mol. Basis Dis. 1362: 103-108.
25. RUSSO, L.M., G.L. BAKRIS & W.D. COMPER. 2002. Renal handling of albumin: a critical review of basic concepts and perspective. Am. J. Kidney Dis. 39: 899-919.
26. MARRA, F., R. DEFRANCO, C. GRAPPONE, et al. 1998. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am. J. Pathol. 152: 423-430.
27. NG, R., O.K. ARGIROV, N. AHMED, et al. 2002. Human serum albumin minimally modified by methylglyoxal binds to human mononuclear leukocytes via the RAGE receptor and is displaced by N-carboxymethyl-lysine and hydroimidazolone AGE epitopes. Int. Congr. Ser. 1245: 77-81.
28. FEHRENBACH, H., R. WEISKIRCHEN, M. KASPER & A.M. GRESSNER. 2001. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 34: 943-952.
29. ZENG, S., N. FEIRT, M. GOLDSTEIN, et al. 2004. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 39: 422-432.
30. THORNALLEY, P.J. 2004. Glycation, receptor-mediated cell activation, and vascular complications of diabetes. Diab. Vac. Dis. Res. 1: 21-22.
31. RIORDAN, S.M., N. SKINNER, A. NACREE, et al. 2003. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 37: 1154-1164.
32. SASS, G., S. HEINLEIN, A. AGLI, et al. 2002. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 19: 115-120.
33. GOLDBERG, A.L. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899.
34. HENLE, T. 2003. AGEs in foods: do they play a role in uremia? Kidney Int. 63: S145-S147.
35. THORNALLEY, P.J. 2003. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419: 31-40.
36. THORNALLEY, P.J. 2003. Glyoxalase I: structure, function, and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans. 31: 1343-1348.
37. BABAEI-JADIDI, R., N. KARACHALIAS, N. AHMED, et al. 2003. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52: 2110-2120.
38. THORNALLEY, P.J., A. YUREK-GEORGE & O.K. ARGIROV. 2000. Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoaldehydes, glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem. Pharmacol. 60: 55-65.
39. RAHMAN, T.M. & H.J.F. HODGSON. 2003. The effects of early and late administration of inhibitors of inducible nitric oxide synthase in a thioacetamide-induced model of acute hepatic failure in the rat. J. Hepatol. 35: 583-590.
40. LE MOINE, O., S. EVRARD, P. EISENDRATH, et al. 2000. Treatment of alcoholic hepatitis with intravenous n-acetylcysteine (NAC): a pilot trial. Gastroenterology 118: 1069.
41. LEVY, S., C. HERVE, E. DELACOUX & S. ERLINGER. 2002. Thiamine deficiency in hepatitis C virus and alcohol-related liver diseases. Digest. Dis. Sci. 47: 543-548.
42. HASSAN, R., H. QURESHI & S.J. ZUBERI. 1991. Effect of thiamine on glucose-utilization in hepatic cirrhosis. J. Gastroenterol. Hepatol. 6: 59-60.
43. PETRIDES, A.S., C. VOGT, D. SCHULZEBERGE, et al. 1994. Pathogenesis of glucose-intolerance and diabetes-mellitus in cirrhosis. Hepatology 19: 616-627.